Evidence map›Paper›PMID 31186672›Full record

ArticleNano today2018

Theranostic Nanosystems for Targeted Cancer Therapy.

Homan Kang, Shuang Hu, Mi Hyeon Cho, Suk Ho Hong, Yongdoo Choi, Hak Soo Choi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano today, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Current Advances on Nanomaterials Interfering with Lactate Metabolism for Tumor Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  12. Article
  13. Article
  14. Review
  15. Carbon nanomaterials for phototherapy.Nanophotonics (Berlin, Germany) · 2022
    Review
  16. HNanoscale research letters · 2022
    Article
  17. Review
  18. Review
  19. NIR fluorescence imaging and treatment for cancer immunotherapy.Journal for immunotherapy of cancer · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Homan Kang *Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Shuang Hu *Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Mi Hyeon ChoBiomarker Branch, National Cancer Center, 323 Ilsan-ro, Goyang, Gyeonggi 10408, South Korea.
Suk Ho HongBiomarker Branch, National Cancer Center, 323 Ilsan-ro, Goyang, Gyeonggi 10408, South Korea.
Yongdoo ChoiBiomarker Branch, National Cancer Center, 323 Ilsan-ro, Goyang, Gyeonggi 10408, South Korea.
Hak Soo ChoiGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Funding

Image-Guided Drug Delivery for Pancreatic Neuroendocrine Tumor.R01EB022230 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI CHOI, HAK SOO, HENARY, MAGED M · 2017 to 2020
$3.6M
NIBIB NIH HHS R01 EB022230
6 · The paper itself

Abstract

Nanomaterials have revolutionized cancer imaging, diagnosis, and treatment. Multifunctional nanoparticles in particular have been designed for targeted cancer therapy by modulating their physicochemical properties to be delivered to the target and activated by internal and/or external stimuli. This review will focus on the fundamental "chemical" design considerations of stimuli-responsive nanosystems to achieve favorable tumor targeting beyond biological barriers and, furthermore, enhance targeted cancer therapy. In addition, we will summarize innovative smart nanosystems responsive to external stimuli (

Indexed as

diagnostic imagingfunctional nanoparticleorgan-specific targetingTargeted therapy

Identifiers

PMID31186672
PMCPMC6559746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.